Biology of bipolar disorder

Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing

Retrieved on: 
Tuesday, June 22, 2021
Medical devices, Surgery, FDA, Genetics, Clinical trials, Stem cells, Other Health, Biotechnology, Pharmaceutical, Health, Branches of biology, Neurotrauma, Spinal cord, Medical emergencies, Biology of bipolar disorder, Oligodendrocyte, Spinal cord injury, Rehabilitation Trauma Center, Lineage Cell Therapeutics

It is a privilege to report that our novel OPC1 program will be returning to clinical testing earlier than anticipated.

Key Points: 
  • It is a privilege to report that our novel OPC1 program will be returning to clinical testing earlier than anticipated.
  • Pursuant to that agreement, Lineage may integrate the Neurgain PSD system into a late-stage clinical trial and, if approved, commercial use of OPC1 for the treatment of patients with spinal cord injury.
  • The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million.
  • OPC1 is an oligodendrocyte progenitor cell (OPC) transplant therapy designed to provide clinically meaningful improvements in motor recovery in individuals with subacute spinal cord injuries.

Innovative Molecules raises €20 million Series A equity financing round

Retrieved on: 
Monday, June 7, 2021
Sexually transmitted diseases and infections, Medical specialties, Biology of bipolar disorder, Herpes simplex, Infectious diseases, Clinical medicine

Munich, Germany, June 7, 2021 - Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its 20 million Series A equity financing round led by LSP (Life Sciences Partners).

Key Points: 
  • Munich, Germany, June 7, 2021 - Innovative Molecules GmbH, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, today announced the closing of its 20 million Series A equity financing round led by LSP (Life Sciences Partners).
  • Joachim Rothe, Partner at LSP, complements: I am pleased with LSP leading the investment syndicate of Innovative Molecules.
  • Thomas Hoffmann, co-founder & financial advisor to Innovative Molecules, states: To have gained LSP as one of the leading European life sciences funds as the lead investor for this Series A financing round is truly a quality stamp for our project.
  • Innovative Molecules GmbH is a drug development company aiming for setting a new treatment standard for Herpes simplex induced diseases.

Toxoplasmosis Treatment Drugs Market Report - Global Size, Share, Outlook, and Opportunity Analysis, 2016-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
General Health, Pharmaceutical, Health, Clinical medicine, Medicine, Conoidasida, Health, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Toxoplasmosis, Zoonoses, Toxoplasma gondii, Chemotherapy

The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Toxoplasmosis Treatment Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Rising number of chemotherapy procedures can lead to increase in the number of toxoplasmosis infection thereby assisting the market growth.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
    The global toxoplasmosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
    Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global toxoplasmosis treatment drugs market.
  • Global Toxoplasmosis Treatment Drugs Market, By Indication:
    Global Toxoplasmosis Treatment Drugs Market, By Route of Administration:
    Global Toxoplasmosis Treatment Drugs Market, By Drug Class:

MBST pursues Nobel Prize-winning research topics

Retrieved on: 
Thursday, May 20, 2021
Articles, Biology of bipolar disorder, Circadian rhythm, Plant cognition, Sleep, Nobel Prize in Physiology or Medicine, Nobel Prize, Magnetic resonance imaging, Science and technology, Branches of biology

The medical significance of this field of science has even been confirmed with a Nobel Prize for Medicine.

Key Points: 
  • The medical significance of this field of science has even been confirmed with a Nobel Prize for Medicine.
  • For its therapy method MBST, the manufacturer MedTec Medizintechnik GmbH has also been active in research around this topic for several years.
  • Awarding of the Nobel Prize for Medicine to Hall, Rosbach and Young for their research of those socalled circadian rhythms of the cells shows the topic\'s significance for the field of medicine.\nDr.
  • Developed on the basis of the technology used in MRI, the gold standard of diagnostics, MBST therapy is without drugs, injections or surgery.

MBST pursues Nobel Prize-winning research topics

Retrieved on: 
Thursday, May 20, 2021
Articles, Biology of bipolar disorder, Circadian rhythm, Plant cognition, Sleep, Nobel Prize in Physiology or Medicine, Nobel Prize, Magnetic resonance imaging, Science and technology, Branches of biology

The medical significance of this field of science has even been confirmed with a Nobel Prize for Medicine.

Key Points: 
  • The medical significance of this field of science has even been confirmed with a Nobel Prize for Medicine.
  • For its therapy method MBST, the manufacturer MedTec Medizintechnik GmbH has also been active in research around this topic for several years.
  • Awarding of the Nobel Prize for Medicine to Hall, Rosbach and Young for their research of those socalled circadian rhythms of the cells shows the topic\'s significance for the field of medicine.\nDr.
  • Developed on the basis of the technology used in MRI, the gold standard of diagnostics, MBST therapy is without drugs, injections or surgery.

Outlook Bipolar Disorder Industry to 2035 - Identify Target Patient Population - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Mental health, Health, Psychiatry, Mood disorders, Abnormal psychology, Psychiatric diagnosis, Bipolar disorder, Depression, Psychology, Bipolar, Biology of bipolar disorder

b'The "Global Bipolar Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Bipolar Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Bipolar Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Bipolar Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Bipolar Disorder patients, history of the disease at the population level (Bipolar Disorder prevalence, Bipolar Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Bipolar Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Bipolar Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Bipolar Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Bipolar Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005591/en/\n'

2021 Epidemiology Forecast for the Global Herpes Market to 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, General Health, Medical specialties, Sexually transmitted diseases and infections, Medicine, Virology, Viral diseases, Biology of bipolar disorder, Herpes simplex, Herpes, Disease

b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Herpes patients, history of the disease at the population level (Herpes prevalence, Herpes incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Herpes patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Herpes market sizing, assessing market potential, and developing drug forecast models\nIdentify Herpes patients segments through age groups, gender, and disease sub-types\n'

Rational Vaccines Licenses Promising Technology from Louisiana State University

Retrieved on: 
Monday, April 5, 2021
Sexually transmitted diseases and infections, Medical specialties, Herpes, Virology, Microbiology, Viral diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, Genital herpes, HSV, Vaccine

CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.

Key Points: 
  • CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.
  • "We are so very excited about adding this incredible science to the Rational Vaccines arsenal and partnering with Louisiana State University in the fight against HSV," said Rational CEO Agustin Fernandez.
  • The VC2 vaccines target facial, ocular and genital herpes caused by HSV-1, but may also provide protection against genital herpes causes by HSV-2.
  • Based in Cambridge, MA, Rational Vx is also joining the battle against COVID-19 with a serological assay currently in development, and a future COVID-19 vaccineplanned.

Nutrition21 Launches Newest Ingredient -- Lustriva™ -- Into the Fast-Growing Beauty-From-Within Market

Retrieved on: 
Monday, March 1, 2021
Chemistry, Physical sciences, Natural sciences, Biology of bipolar disorder, Biology of obsessive–compulsive disorder, Inositol, Biotin, Boron

1, 2021 /PRNewswire/ --Nutrition21, LLC ("Nutrition21") has announced the launch of its latest ingredient, Lustriva, a clinically tested beauty-from-within ingredient that contains Bonded Arginine Silicate (arginine silicon inositol complex) and Magnesium Biotinate (Nutrition21's proprietary biotin formulation).

Key Points: 
  • 1, 2021 /PRNewswire/ --Nutrition21, LLC ("Nutrition21") has announced the launch of its latest ingredient, Lustriva, a clinically tested beauty-from-within ingredient that contains Bonded Arginine Silicate (arginine silicon inositol complex) and Magnesium Biotinate (Nutrition21's proprietary biotin formulation).
  • Studies have also demonstrated that Lustriva can enhance hair growth and density and improve skin elasticity and overall appearance.
  • James Komorowski, MS, CNS, Chief Science Officer of Nutrition21, commented, "This is an exciting launch for Nutrition21, and we are proud to bring this clinically tested, patent-protected ingredient to the beauty market.
  • Science is the biggest differentiator for Lustriva and gives us confidence that the market and consumers will embrace it.

Leading Scientist Dr. Konstantin Kousoulas Shares His Mission to Eradicate Herpes

Retrieved on: 
Monday, March 1, 2021
Medical specialties, Biology of bipolar disorder, Herpes simplex, Gus Fring, HSV, Fictional characters, Clinical medicine

CAMBRIDGE, Mass., March 1, 2021 /PRNewswire/ -- By 1999 Dr. Konstantin 'Gus' Kousoulas was a tenured professor and consultant.

Key Points: 
  • CAMBRIDGE, Mass., March 1, 2021 /PRNewswire/ -- By 1999 Dr. Konstantin 'Gus' Kousoulas was a tenured professor and consultant.
  • Scientist hopes to fufill his father's challenge to do something positive for humanity and to help put an end to HSV.
  • People like you that are this smart, you should do something as opposed to just (making money)," Kousoulas said.
  • It was as a young scientist he first began to understand the impact herpes has on everyday people.